Elizabeth A Evans1, Donna Wilson2, Peter D Friedmann3. 1. Department of Health Promotion and Policy, School of Public Health and Health Sciences, University of Massachusetts Amherst, 312 Arnold House, 715 North Pleasant Street, Amherst, MA 01003, USA. Electronic address: eaevans@umass.edu. 2. University of Massachusetts Chan Medical School (UMCMS) - Baystate and Baystate Health, Springfield, MA, USA. Electronic address: Donna.Wilson@baystatehealth.org. 3. University of Massachusetts Chan Medical School (UMCMS) - Baystate and Baystate Health, Springfield, MA, USA. Electronic address: peter.friedmannmd@baystatehealth.org.
Abstract
BACKGROUND: Buprenorphine is an effective medication for opioid use disorder (MOUD) when offered in community-based settings, but evidence is limited for incarcerated populations, particularly in relation to recidivism. In Massachusetts, Franklin County jail (FCSO) was among the first to provide buprenorphine; adjacent Hampshire County jail (HCHC) offered it more recently. These jails present a natural experiment to determine whether outcomes are different between individuals who did and did not have the opportunity to receive buprenorphine in jail. METHODS: We examined outcomes of all incarcerated adults with opioid use disorder (n = 469) who did (FCSO n = 197) and did not (HCHC n = 272) have the opportunity to receive buprenorphine. The primary outcome was post-release recidivism, defined as time from jail exit to a recidivism event (incarceration, probation violation, arraignment). Using Cox proportional hazards models, we investigated site as a predictor, controlling for covariates. We also examined post-release deaths. RESULTS: Fewer FCSO than HCHC individuals recidivated (48.2% vs. 62.5%; p = 0.001); fewer FCSO individuals were re-arraigned (36.0% vs. 47.1%; p = 0.046) or re-incarcerated (21.3% vs. 39.0%; p < 0.0001). Recidivism risk was lower in the FCSO group (hazard ratio 0.71, 95% confidence interval 0.56, 0.89; p = 0.003), net of covariates (adjusted hazard ratio 0.68, 95% confidence interval 0.53, 0.86; p = 0.001). At each site, 3% of participants died. CONCLUSIONS: Among incarcerated adults with opioid use disorder, risk of recidivism after jail exit is lower among those who were offered buprenorphine during incarceration. Findings support the growing movement in jails nationwide to offer buprenorphine and other agonist medications for opioid use disorder. Published by Elsevier B.V.
BACKGROUND: Buprenorphine is an effective medication for opioid use disorder (MOUD) when offered in community-based settings, but evidence is limited for incarcerated populations, particularly in relation to recidivism. In Massachusetts, Franklin County jail (FCSO) was among the first to provide buprenorphine; adjacent Hampshire County jail (HCHC) offered it more recently. These jails present a natural experiment to determine whether outcomes are different between individuals who did and did not have the opportunity to receive buprenorphine in jail. METHODS: We examined outcomes of all incarcerated adults with opioid use disorder (n = 469) who did (FCSO n = 197) and did not (HCHC n = 272) have the opportunity to receive buprenorphine. The primary outcome was post-release recidivism, defined as time from jail exit to a recidivism event (incarceration, probation violation, arraignment). Using Cox proportional hazards models, we investigated site as a predictor, controlling for covariates. We also examined post-release deaths. RESULTS: Fewer FCSO than HCHC individuals recidivated (48.2% vs. 62.5%; p = 0.001); fewer FCSO individuals were re-arraigned (36.0% vs. 47.1%; p = 0.046) or re-incarcerated (21.3% vs. 39.0%; p < 0.0001). Recidivism risk was lower in the FCSO group (hazard ratio 0.71, 95% confidence interval 0.56, 0.89; p = 0.003), net of covariates (adjusted hazard ratio 0.68, 95% confidence interval 0.53, 0.86; p = 0.001). At each site, 3% of participants died. CONCLUSIONS: Among incarcerated adults with opioid use disorder, risk of recidivism after jail exit is lower among those who were offered buprenorphine during incarceration. Findings support the growing movement in jails nationwide to offer buprenorphine and other agonist medications for opioid use disorder. Published by Elsevier B.V.
Entities:
Keywords:
Buprenorphine; Criminal justice settings; Massachusetts Justice Community Opioid Innovation Network (MassJCOIN); Medications for opioid use disorder (MOUD); Mortality; Naltrexone; Recidivism
Authors: Alexandria Macmadu; William C Goedel; Joëlla W Adams; Lauren Brinkley-Rubinstein; Traci C Green; Jennifer G Clarke; Rosemarie A Martin; Josiah D Rich; Brandon D L Marshall Journal: Drug Alcohol Depend Date: 2020-01-18 Impact factor: 4.492
Authors: Lia N Pizzicato; Rebecca Drake; Reed Domer-Shank; Caroline C Johnson; Kendra M Viner Journal: Drug Alcohol Depend Date: 2018-06-05 Impact factor: 4.492
Authors: Sandra A Springer; Angela Di Paola; Marwan M Azar; Russell Barbour; Breanne E Biondi; Maureen Desabrais; Thomas Lincoln; Daniel J Skiest; Frederick L Altice Journal: J Acquir Immune Defic Syndr Date: 2018-05-01 Impact factor: 3.731
Authors: Stephen Magura; Joshua D Lee; Jason Hershberger; Herman Joseph; Lisa Marsch; Carol Shropshire; Andrew Rosenblum Journal: Drug Alcohol Depend Date: 2008-10-18 Impact factor: 4.492
Authors: Elizabeth A Evans; Thomas J Stopka; Ekaterina Pivovarova; Sean M Murphy; Faye S Taxman; Warren J Ferguson; Dana Bernson; Claudia Santelices; Kathryn E McCollister; Randall Hoskinson; Thomas Lincoln; Peter D Friedmann Journal: J Subst Abuse Treat Date: 2021-01-08
Authors: Elizabeth A Evans; Ekaterina Pivovarova; Thomas J Stopka; Claudia Santelices; Warren J Ferguson; Peter D Friedmann Journal: J Subst Abuse Treat Date: 2022-02-23